Mild Persistent Asthma Clinical Trial
Official title:
A Double-blind, Randomized, Cross-over Design Study to Compare the Lung Function Measure of Montelukast Versus Placebo in Children With Mild Persistent Asthma
This study aims to identify markers to prove rapid improvement of lung function, airway inflammation and bronchodilator response after 2-week LTRA administration.
This study is a randomized, double-blind, placebo-controlled, cross-over study with a washout
period of at least one week between each study period.
After an initial screening visit, subjects entered a screening period of one to two weeks to
ensure clinical stability without medication, which means absence of daily asthma symptoms.
Eligible subjects were randomized into either the treatment portion of the trial, in which
subjects received montelukast (4 mg or 5 mg) or matching placebo monotherapy in a randomized
manner. During each treatment period, which lasted 2 weeks, the study medication was
administered between 8:00 and 9:00 A.M. Short acting bronchodilator (for severe symptoms) was
permitted during the study period but was withheld 24 hours prior to bronchodilator challenge
test.
Inclusion criteria will be mild persistent asthma children old enough to cooperate on
performing pulmonary function testing, children with no respiratory symptoms 4 weeks prior to
the beginning of the study. Exclusion criteria will be the following: respiratory symptoms
including cough, wheezing, dyspnea, or shortness of breath, presence of acute or chronic
upper respiratory infections, anatomical nasal disorders (ex, nasal polyps, septum deviation,
etc.), previous or current specific immunotherapy, use of systemic corticosteroids, or
admission or visit of the emergency department during the previous 4 weeks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01591343 -
Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma
|
Phase 2 | |
Completed |
NCT02063139 -
Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.
|
Phase 2 | |
Completed |
NCT01343745 -
Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)
|
Phase 2 | |
Completed |
NCT02584257 -
Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma
|
Phase 3 |